Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Apetamin is a combination vitamin syrup marketed as an appetite stimulant and weight gain supplement. It is manufactured by TIL Healthcare and contains cyproheptadine hydrochloride, L-lysine, and a complex of B vitamins including thiamine, pyridoxine, nicotinamide, and dexpanthenol. Cyproheptadine, the primary active component, is a first-generation antihistamine and serotonin antagonist that promotes appetite as a side effect. Although cyproheptadine is FDA-approved for allergic conditions, Apetamin itself is not approved by the FDA, UK MHRA, or Health Canada. It is frequently sold illicitly via social media for cosmetic body enhancement and has been linked to serious adverse events, including hepatotoxicity and drug-induced autoimmune hepatitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Apetamin.